RxDoctor Payments Data

Abidemi Idowu, MD

Pulmonary Disease · Pine Bluff, ARNPI 1427544907

Payments from drug & device makers

$2,140in general payments, 2019–2025

Across 101 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$594
  • AstraZeneca$319
  • Regeneron Healthcare Solutions, Inc.$318
  • Sanofi$185
  • Amgen$152
  • Insmed, Inc.$124
  • plus $449 from 7 others

What the payments were for

  • Food & beverage$2,03495%
  • Education$1065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,140 in reported general payments places this provider in the 30th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$29,363
Medicare patients
116
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate12$155,552
Spiriva HandihalerTiotropium Bromide15$11,198
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,482
Incruse ElliptaUmeclidinium Bromide17$9,246
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,392
SymbicortBudesonide/Formoterol Fumarate27$5,977
Albuterol Sulfate HfaAlbuterol Sulfate128$3,474
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,560
Montelukast Sodium30$269
Fluticasone Propionate14$146
Prednisone14$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$97$155,55212 claims
GSKIncruse Ellipta, Trelegy Ellipta$594$17,63830 claims
AstraZenecaBreztri Aerosphere, Symbicort$319$15,45940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →